NCT03973177 — drugset

Summary

Chronic knee pain from osteoarthritis (OA) is commonly treated with total knee arthroplasty (TKA) when conservative therapies fail to provide pain relief. More than 600,000 TKAs are performed in the U.S. annually, a number that continues to increase. A logistic-regression model suggests that the incidence rate of TKA will increase by 143% in the United States by 2050 compared to 2012. Although TKA is successful in reducing knee pain and joint stiffness in most cases, it can be associated with a 7-35% incidence of persistent refractory post-surgical knee pain. Aim: To determine whether chemical neurolysis of the genicular nerves with 6% aqueous phenol is non-inferior in reducing knee pain as compared to corticosteroid injection of the genicular nerves, in patients with refractory chronic knee pain for more than 6 months after total knee replacement. Hypothesis: Chemical neurolysis of genicular nerves with phenol will provide equal or superior pain relief than corticosteroid genicular nerve injections at 3 months, as measured by the Oxford Knee Score.

Timeline

Start: 2019-05-24
Primary completion: 2022-07
Completion: 2023-03

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylprednisolone	Other / unclassified	10 mg	Other
Subject	Phenol	Other / unclassified	2.5 ml	Other
Subject	Phenol	Other / unclassified	6 %	Other
Background	Phenol Injection	Unknown	0.5 ml	—

Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain

Summary

Timeline

Publications

Drugs

Indications